Cargando…

Epidemiologic and Molecular Pathophysiology of Chronic Opioid Dependence and the Place of Naltrexone Extended-Release Formulations in its Clinical Management

Naltrexone implants and depot injections (NI) are a novel form of treatment for opiate dependence (OD). Major questions relate to their absolute and relative efficacy and safety. Opportunely, six recent clinical trial data from several continents have uniformly provided dramatic evidence of the pote...

Descripción completa

Detalles Bibliográficos
Autor principal:	Reece, Albert Stuart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465087/ https://www.ncbi.nlm.nih.gov/pubmed/23055738 http://dx.doi.org/10.4137/SART.S9031

Ejemplares similares

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015)

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
por: Earley, Paul H., et al.
Publicado: (2017)

Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2022)

Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence
por: Li, Xinyi, et al.
Publicado: (2023)

Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence
por: Wang, A-L, et al.
Publicado: (2015)

Medication Treatment for Opioid Use Disorders:: A Brief Overview with Comments on Extended Release Naltrexone
por: Woody, George
Publicado: (2017)

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
por: Marciuch, Anne, et al.
Publicado: (2023)

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
por: Parchinski, Kaley, et al.
Publicado: (2023)

Effects of Naltrexone on Pain Sensitivity and Mood in Fibromyalgia: No Evidence for Endogenous Opioid Pathophysiology
por: Younger, Jarred W., et al.
Publicado: (2009)

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
por: Kunøe, Nikolaj, et al.
Publicado: (2016)

The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature
por: Ramsey, Susan E., et al.
Publicado: (2016)

Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
por: Jain, Priya, et al.
Publicado: (2020)

Naltrexone long-acting formulation in the treatment of alcohol dependence
por: Johnson, Bankole A
Publicado: (2007)

Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2021)

Whose mu fared better? The effect of extended-release naltrexone (XR-NTX) on treatment outcomes for opioid and alcohol users
por: Crèvecoeur-MacPhail, Desirée A
Publicado: (2015)

Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis
por: Hoffman, Kim A., et al.
Publicado: (2021)

Pharmacological enhancement of naltrexone treatment for opioid dependence: a review
por: Mannelli, Paolo, et al.
Publicado: (2011)

Long-Acting Injectable Naltrexone for the Management of Patients with Opioid Dependence
por: Kjome, Kimberly L., et al.
Publicado: (2011)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients
por: Zaaijer, Eline R., et al.
Publicado: (2015)

Naltrexone Implant for Opioid Use Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021)

Adapting treatment length to opioid‐dependent individuals’ needs and preferences: a 2‐year follow‐up to a 1‐year study of extended‐release naltrexone
por: Solli, Kristin Klemmetsby, et al.
Publicado: (2021)

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
por: Mannelli, Paolo, et al.
Publicado: (2022)

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
por: Pergolizzi, Joseph V, et al.
Publicado: (2018)

Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study)
por: Weimand, B.M., et al.
Publicado: (2021)

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
por: Comer, Sandra D., et al.
Publicado: (2020)

Factors associated with willingness to take extended release naltrexone among injection drug users
por: Ahamad, Keith, et al.
Publicado: (2015)

Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study
por: Marciuch, Anne, et al.
Publicado: (2022)

Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States
por: Iwanicki, Janetta L., et al.
Publicado: (2016)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials
por: Murphy, Sean M., et al.
Publicado: (2020)

The Vivitrol pilot program (VPP): initial quantitative findings from an extended-release naltrexone study
por: Rieckmann, Traci, et al.
Publicado: (2015)

Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
por: Hong, K., et al.
Publicado: (2016)

Reduction in arterial stiffness and vascular age by naltrexone-induced interruption of opiate agonism: a cohort study
por: Reece, Albert Stuart, et al.
Publicado: (2013)

Naltrexone and the Treatment of Alcohol Dependence
por: Volpicelli, Joseph R., et al.
Publicado: (1994)

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Caixàs, Assumpta, et al.
Publicado: (2014)

The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis
por: Zangiabadian, Moein, et al.
Publicado: (2022)

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
por: Nguyen, Thuy, et al.
Publicado: (2022)

Comment on “Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence”
por: Silverman, Bernard, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fla7rm4arqhhjakav42o0tr0dd